Amlodipine in angina pectoris: effect on maximal and submaximal exercise performance.
Amlodipine, a dihydropyridine calcium antagonist, was compared with placebo in a double-blind cross-over study in 16 patients with angina. After a 2-week single-blind placebo period, patients entered a double-blind crossover phase alternating between 4 weeks of placebo and 4 weeks of amlodipine, 10 mg once daily. The two 4-week periods were separated by a 1-week single-blind placebo washout period. The efficacy of drug therapy was measured using frequency of angina, nitroglycerin consumption, peak oxygen consumption during a maximal treadmill exercise test, and endurance time during a separate submaximal exercise test performed at 70% of the peak work capacity that had been determined before randomization. Compared with single-blind placebo there was a reduction in angina frequency during double-blind placebo and amlodipine, whereas nitroglycerin consumption was significantly reduced only by amlodipine. Amlodipine produced a significant increase in peak oxygen consumption and endurance time during the submaximal exercise test when compared with single-blind and double-blind placebo periods. Patients tolerated both placebo and amlodipine without clinically significant side effects.
Kinnard
D R
DR
Department of Medicine, University of Colorado Health Sciences Center, Denver.
Harris
M
M
Hossack
K F
KF
D000368:Aged; D017311:Amlodipine; D000787:Angina Pectoris / Q000188:drug therapy* / Q000503:physiopathology; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000627:therapeutic use*; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010807:Physical Endurance
D002121:Calcium Channel Blockers; D017311:Amlodipine; D009543:Nifedipine